‘We believe our stage II study would represent probably the most advanced stem cell research conducted to date,’ said William M. Caldwell IV, ACT’s Chairman and CEO. ‘Furthermore to evaluating our medical options, the Company is also considering the most effective way to finance the cost of the study, that could include grants, partnerships or capital supplied by foundations. We are also in negotiations with several countries in European countries to conduct an identical trial. The marketplace potential in the EU is normally even greater than in the U.S. By up to 50 percent in patient people size by some estimates.’ The FDA has provided ACT clearance to proceed with a Phase II trial, which is expected to start in the first half of 2011.Approximately one third of these osteoclasts were giant and detached. Although a considerably higher amount of normal-showing up osteoclasts was present in the group receiving 10 mg of alendronate per day than in the placebo group, the reduction in biochemical markers and the increase in bone mineral density claim that also the normal-showing up osteoclasts resorbed bone poorly. Normally, the true amount of osteoclasts is usually a faithful index of bone resorption,21 but obviously, this is not accurate after treatment with alendronate.